In the present study, we have found that GLS inhibitor CB-839 can significantly repress human ESCC cell-derived xenografts, chemical carcinogen-induced primary ESCC and PDXs in mice and the effect is more pronounced and sometimes only observed in tumors overexpressing TIGAR. This evidence concerns the gene GLS and esophageal squamous cell carcinoma.